ArdorComm Media Group

Contact Us
Friday, April 3, 2026 2:54 AM
logo
Menu
logo

Health & Wellness Community

Controversial ‘Pay Clinic’ Proposal Sparks Concerns Over Privatization of Health Sector

/ Health & Wellness Community

The Punjab Health Department is thinking about implementing a “Pay Clinic” model. A private practice within government health facilities would be an option for specialists under this proposed scheme, with fees collected going to the doctors, support staff, and the facilities themselves. India’s Doctors for Peace and Development (IDPD) have serious concerns about the ‘Pay Clinic’ initiative, despite the government’s claim that it is meant to maintain specialist and super-specialist services in the public sector. As per the doctors’ body, this initiative is viewed as a cautious attempt to weaken the public health system, which could lead to the eventual privatization of the health sector. Critics contend that the comparatively low pay scale in the state is the main reason why physicians choose to work in private practices. The president of IDPD, Dr. Arun Mitra, claims that it is unsustainable for the government to claim that this program will support specialists. He contends that improving public hospitals’ facilities and infrastructure will be crucial to finding a workable solution by drawing in more medical professionals. The ‘Pay Clinic’ system that is being proposed would permit physicians to hold private consultations on hospital property after regular business hours. Dr. Mitra underlines that the government’s inability to draw physicians to state services as a result of insufficient health spending is the main problem. He highlights the need for more public investment in health care even more by pointing out that Punjab has the highest out-of-pocket health care costs in the nation. Another IDPD member, Dr. Indervir Gill, expresses worries about the possible effects on lower-class communities. Due to financial limitations, this population, which was previously dependent on state facilities, may now experience increased financial burdens. Dr. Gill cites guidelines from the World Health Organization that state governments ought to devote at least 5% of their GDP to the health sector. He draws attention to the fact that the Punjabi government, which ranks lowest in the NITI Aayog Index for healthcare allocation, and the Union government both fall short of this standard.

Controversial ‘Pay Clinic’ Proposal Sparks Concerns Over Privatization of Health Sector Read More »

BMC Unveils ₹1,500 Crore ‘Healthcare at Doorstep’ Initiative: Digital Health Mission to Transform Medical Services in Maharashtra

/ Health & Wellness Community

The Brihanmumbai Municipal Corporation (BMC) in Maharashtra is planning to launch a groundbreaking healthcare initiative with a 1,500 crore budget. The ‘Chief Minister Health at Doorstep Scheme,’ which aims to reduce out-of-pocket healthcare costs, is expected to provide a wide range of medical services directly to residents. Sudhakar Shinde, BMC Additional Municipal Commissioner, announced the initiative at the CII Hospital Tech summit, emphasizing the importance of diagnostics for people over the age of 60. The scheme will include services such as doorstep delivery of over 4,500 drug-consumable items, as well as blood sample collection. BMC’s commitment to healthcare is reflected in its allocation of 15% of its budget to the sector, which is higher than the percentage allocated by most states in the country. Shinde urged industry to help with the initiative by providing skilled medical professionals, IT support, and innovative solutions. Collaboration with the private sector is critical to the program’s success in providing quality healthcare to Mumbai residents. N Nawin Sona, Principal Secretary of the Maharashtra Government’s Public Health Department, emphasized the importance of technology adoption in order to reduce healthcare costs. He outlined the government’s plan to improve healthcare access, accountability, and affordability. Sona also emphasized the importance of health data alignment between the public and private sectors, as well as the establishment of a health registry. The Maharashtra Government is actively pursuing the Digital Health Mission in line with its commitment to technological advancements in healthcare. The government intends to work with the private sector to carry out this mission, emphasizing the importance of public-private partnerships in transforming healthcare delivery. The initiative is a forward-thinking approach that leverages technology to improve healthcare services and make them more convenient and affordable for Maharashtra residents.

BMC Unveils ₹1,500 Crore ‘Healthcare at Doorstep’ Initiative: Digital Health Mission to Transform Medical Services in Maharashtra Read More »

US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy

/ Health & Wellness Community

Ahead of an upcoming meeting of independent experts, the U.S. health regulator’s staff has raised doubts about the adequacy of data supporting Merck’s chronic cough drug’s meaningful benefits, according to documents released on Wednesday. Merck’s shares dropped nearly 1 percent to $101.2 in afternoon trade following the news. This concern emerged after Merck submitted additional efficacy data for the drug, which the U.S. Food and Drug Administration (FDA) had previously rejected in January of the previous year. A panel of expert advisers to the FDA is scheduled to meet on Friday to assess the efficacy of Merck’s drug, gefapixant. The panel will specifically consider whether the data provided by Merck demonstrates that the reduction in cough frequency achieved with gefapixant is clinically significant for patients. Currently, there are no approved therapies for chronic cough in the United States. Globally, approximately 10 percent of the adult population is estimated to be affected by this condition, with about half of these individuals lacking an identifiable cause for their cough despite diagnostic tests. Gefapixant functions by blocking receptors that stimulate nerves, thereby suppressing the urge to cough. The drug underwent evaluation in two late-stage trials, where a higher dose demonstrated a statistically significant reduction in the average number of coughs per hour over a 24-hour period compared to a placebo. While the European Union and Japan have granted approval for Merck’s drug under the brand name Lyfnua, the FDA staff’s concerns highlight uncertainties about its efficacy in the U.S. market.

US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy Read More »

AI Predicted to Propel Medical Devices Industry to $1.2 Billion by 2027, Indicates GlobalData Report

/ Health & Wellness Community

According to a report from GlobalData, a leading data and analytics company, the medical devices industry is anticipated to reach $1.2 billion by 2027, primarily fueled by the healthcare sector’s need to streamline processes, cut costs, and enhance accuracy in diagnosing an increasing number of patients with intricate medical profiles. Brian Hicks, Senior Analyst of Medical Devices at GlobalData, highlighted the widespread use of AI in healthcare, particularly in diagnostic settings, where AI algorithms expedite the identification of challenging image abnormalities that might be overlooked by the human eye. This advancement allows for a more comprehensive review of patient profiles while minimizing the risk of misdiagnoses. The report emphasizes that the driving force behind this surge is the adoption of computer vision technology, which finds applications in diagnostics across various medical specialties. Notably, AI’s contribution to reducing error rates in cancer detection has been well-documented, with studies indicating a significant decrease in pathologists’ error rates, from 3.4% to 0.5%, when AI was incorporated in identifying cancer-positive lymph nodes as far back as 2016. Hicks emphasized the accelerated pace at which AI can identify potential positive cases, allowing for a more rapid review of numerous patient profiles without compromising accuracy. The research reveals a notable concentration of AI-related investments in the medical imaging and diagnostic sectors, with many companies specializing in leveraging deep learning technology. Traditional MedTech companies, primarily focused on hardware and surgical instruments, have limited opportunities to integrate such advanced technologies into their products. Hicks underscored the critical role of AI in early detection, asserting that its ability to analyze challenging tissue abnormalities, symptoms, and intricate patient profiles will lead to earlier interventions and improved patient outcomes.

AI Predicted to Propel Medical Devices Industry to $1.2 Billion by 2027, Indicates GlobalData Report Read More »

Scientists Concerned About New COVID Variant ‘JN.1’ with Increased Infectiousness and Potential Vaccine Immunity Evasion

/ Health & Wellness Community

Scientists are expressing concern about the latest COVID-19 variant, named ‘JN.1’, as it appears to be more infectious and potentially capable of evading vaccine immunity. This variant was first identified in Luxembourg on August 25, 2023, and has since been detected in several countries, including England, Iceland, France, and the United States. What particularly worries scientists is the significant number of genetic differences in JN.1 compared to other prominent COVID strains like XBB.1.5 and HV.1. XBB.1.5 is the primary target of the latest vaccine boosters in the United States, and most new variants are descendants of this strain, indicating that existing vaccines are effective against them. HV.1, while somewhat different from XBB.1.5, shares similarities with its parent strain. However, JN.1 stands out due to its substantial divergence. In comparison to XBB.1.5, HV.1 has ten additional unique mutations, but JN.1 boasts a striking 41 additional unique mutations. A significant portion of these mutations is found in the spike protein of the virus, which is associated with increased infectivity and potential immune evasion. This raise concerns that current vaccines may not be as effective against this variant. Dr. Thomas Russo, the chief of infectious diseases at the University of Buffalo in New York, stated that JN.1’s spike protein mutation makes it particularly adept at evading the immune response, which could lead to a higher risk of infections. Moreover, there is some evidence suggesting that JN.1’s parent variant, BA.2.86, may be more transmissible than earlier versions of the virus. This high degree of variability in the spike protein, which was first observed in the alpha and beta versions of SARS-CoV-2 in 2021, is a noteworthy aspect of JN.1’s genetic makeup. While these developments raise concerns, the U.S. Centers for Disease Control and Prevention (CDC) have indicated that initial data suggests updated COVID vaccines should still provide protection against JN.1. They also stated that treatments and testing measures are expected to remain effective against this variant, based on an analysis from the federal government’s SARS-CoV-2 Interagency Group.

Scientists Concerned About New COVID Variant ‘JN.1’ with Increased Infectiousness and Potential Vaccine Immunity Evasion Read More »

Study in India Reveals Link Between Air Pollution and Type 2 Diabetes Risk

/ Health & Wellness Community
News on Health

Air pollution in India has been linked to an increased risk of type 2 diabetes, as revealed in a groundbreaking study published in the BMJ Open Diabetes Research and Care journal. The study, the first of its kind in India, was conducted in Delhi and Chennai, and it found that exposure to elevated levels of fine pollution particles (PM2.5) in the air, which are 30 times thinner than a strand of hair, is associated with higher blood sugar levels and an elevated incidence of type 2 diabetes. While the health impacts of fine particulate matter are known for cardiovascular and cardiometabolic diseases, this study sought to provide evidence from regions with high air pollution levels like India, where noncommunicable diseases are a significant burden. The research team, which included scientists from the Centre for Chronic Disease Control in New Delhi, followed a group of over 12,000 men and women from 2010 to 2017, regularly measuring their blood sugar levels. They also utilized satellite data and air pollution exposure models to assess air quality in the participants’ localities during that period. The results demonstrated that exposure to PM2.5 for just one month led to increased blood sugar levels, and prolonged exposure for a year or more elevated the risk of diabetes. Additionally, for every 10 micrograms per cubic meter (μg/m3) increase in the annual average PM2.5 levels in Delhi and Chennai, the risk of diabetes rose by 22 percent. The study addressed a significant research gap in South Asia, where diabetes is a major health concern, by providing robust exposure assessment and longitudinal data in this population. It underscores the need for tailored, population-specific policies to combat the high diabetes prevalence by reducing ambient air pollution. The research team, which also included scientists from the Public Health Foundation of India, Harvard University, Emory University, the All India Institute of Medical Sciences, and the Madras Diabetes Research Foundation, emphasized the importance of region-specific measures to achieve meaningful public health improvements at the population level.

Study in India Reveals Link Between Air Pollution and Type 2 Diabetes Risk Read More »

COVID Vaccination Doesn’t Increase Risk of Sudden Deaths Among Young Adults in India: Study

/ Health & Wellness Community

A study conducted by the Indian Council of Medical Research (ICMR) has found that COVID-19 vaccination does not raise the risk of sudden deaths among young adults in India. The research, titled “Factors associated with sudden deaths among adults aged 18-45 years in India,” is currently undergoing peer review and is yet to be published. The study’s findings indicate that factors such as previous hospitalization for COVID-19, binge drinking, and intense physical activity shortly before death are more likely to increase the risk of sudden deaths in this age group. Union Health Minister Mansukh Mandaviya, referencing the ICMR study, advised individuals who had experienced severe COVID-19 not to exert themselves excessively for a year or two to reduce the risk of heart attacks and cardiac arrests. The study was initiated due to concerns about anecdotal reports of sudden deaths among healthy young adults in India, potentially related to COVID-19 or vaccination. It analyzed cases of seemingly healthy individuals aged 18-45 who died suddenly from unexplained causes between October 1, 2021, and March 31, 2023. The research collected information on their medical history, behaviors, COVID-19 hospitalization, and vaccine doses administered, concluding that COVID-19 vaccination actually reduces the risk of sudden deaths among young adults in India. This study offers valuable insights into the factors contributing to such occurrences in this demographic.

COVID Vaccination Doesn’t Increase Risk of Sudden Deaths Among Young Adults in India: Study Read More »

Strides Pharma Sells Singapore Plant for $15M to Reduce Debt and Costs

/ Health & Wellness Community

Strides Pharma Science (Strides) has recently announced a significant development in its strategic restructuring efforts. The company has signed a binding agreement with Rxilient Biohub to sell its manufacturing facility in Singapore for a total of $15 million. The proceeds from this transaction will be allocated towards reducing the company’s debt. This sale also promises to yield substantial cost savings for Strides, with an annual reduction of INR 75 crore. Of this amount, INR 18 crore will be attributed to a decrease in operating expenses, while INR 57 crore will pertain to depreciation and operating lease expenses. It’s important to note that this transaction will not have any adverse impact on the company’s revenues and is expected to be earnings per share (EPS) accretive. The Singapore manufacturing facility had been inactive since the previous year as part of Strides’ broader strategy to optimize its manufacturing network and cut costs, which was unveiled as part of the FY23 reset strategy. Strides has been directing its efforts towards integrating its operations in the United States, and products previously supplied for US government procurement have already been transitioned to the Chestnut Ridge manufacturing site in the US. The company views this sale as the culmination of its ongoing manufacturing network optimization efforts, aligning with its core objectives of enhancing profitability and operational efficiency. The completion of this transaction is anticipated in the third quarter of FY24, contingent upon the receipt of necessary approvals.

Strides Pharma Sells Singapore Plant for $15M to Reduce Debt and Costs Read More »

WHO Calls for Regulation of AI in Healthcare Due to Risks, Citing Bias and Privacy Concerns

/ Health & Wellness Community
News on Health

The World Health Organization (WHO) is calling for the regulation of artificial intelligence (AI) in healthcare due to the associated risks, according to a report. WHO emphasizes the need to establish safety and efficacy in AI tools, make them accessible to those who require them, and encourage communication among AI developers and users. While recognizing AI’s potential to enhance healthcare by strengthening clinical trials, improving diagnosis and treatment, and enhancing healthcare professionals’ knowledge and skills, the report by data and analytics company GlobalData highlights the rapid deployment of AI technologies without a full understanding of their long-term implications, which could pose risks to healthcare professionals and patients. Alexandra Murdoch, a Senior Analyst at GlobalData, acknowledges the significant benefits of AI in healthcare but also highlights the risks associated with rapid adoption. AI systems in healthcare often have access to personal and medical information, necessitating regulatory frameworks to ensure privacy and security. Other challenges with AI in healthcare include unethical data collection, cybersecurity vulnerabilities, and the reinforcement of biases and dissemination of misinformation. An example of AI biases is found in a Stanford University study, which revealed that some AI chatbots provided inaccurate medical information about people of color. In this study, nine questions were posed to four AI chatbots, including OpenAI’s ChatGPT and Google’s Bard, and all four chatbots provided inaccurate information related to race and kidney and lung function. The use of such false medical information is a cause for concern, as it could lead to issues like misdiagnoses and improper treatment for patients of color. WHO has identified six areas for regulating AI in healthcare, with a focus on managing the risks associated with AI amplifying biases in training data. These areas for regulation include transparency and documentation, risk management, data validation and clarity of AI’s intended use, a commitment to data quality, privacy and data protection, and the promotion of collaboration. Alexandra Murdoch hopes that by outlining these regulatory areas, governments and regulatory bodies can develop regulations to safeguard healthcare professionals and patients while fully harnessing the potential of AI in healthcare.

WHO Calls for Regulation of AI in Healthcare Due to Risks, Citing Bias and Privacy Concerns Read More »